Hepatitis C News and Research

Latest Hepatitis C News and Research

Evaluating patients for genetic variations impacts adherence to antiviral therapy

In two recent studies, researchers have identified two functional variants in the inosine triphosphatase (ITPA) gene that protect patients with hepatitis C virus (HCV) against anemia brought on by antiviral treatment. The ability to identify those patients protected against treatment-induced anemia will ensure completion of antiviral therapy and successful elimination of the virus.

25 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

CRI, Oncovir sign new investment agreement to produce immunological stimulant

Cancer Research Institute, a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund, a joint initiative with the Ludwig Institute for Cancer Research, has completed a new investment agreement with Oncovir, a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol- (Poly-ICLC).

24 Jan 2011

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization founded in 1953 to advance the science of tumor immunology and foster the discovery and development of new cancer immunotherapies, announced today that its Cancer Vaccine Acceleration Fund (CVAF), a joint initiative with the Ludwig Institute for Cancer Research (LICR), has completed a new investment agreement with Oncovir, Inc., a biotechnology company based in Washington, D.C., to enable the production of the immunological stimulant Hiltonol® (Poly-ICLC).

21 Jan 2011

Pharmasset prices underwritten public offering of 3,300,000 shares of common stock

Pharmasset, Inc. announced today the pricing of an underwritten public offering of 3,300,000 shares of its common stock at an offering price of $46.33 per share. Of the shares being sold, Pharmasset is selling 2,300,000 shares and the selling stockholders are selling 1,000,000 shares. Pharmasset expects to receive net proceeds, after deducting the underwriting discount and estimated offering expenses, of approximately $101.5 million.

21 Jan 2011

Opinions: GAVI; Haitian women; Clinton's foreign policy

"Vaccines are among the greatest scientific contributions to human welfare. They are also some of the largest humanitarian contributions of developed nations to the rest of the world. So it is unfortunate that a decade of vaccine controversy has overshadowed a decade of vaccine miracles," Washington Post columnist Michael Gerson writes in an opinion piece reflecting on the contributions of the GAVI Alliance over the past decade.

21 Jan 2011

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the company's request for six-month Priority Review. Telaprevir is Vertex's lead medicine in development for people with genotype 1 chronic hepatitis C.

20 Jan 2011

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism.

20 Jan 2011

El Camino Hospital introduces CHI program to educate Chinese community on health disparities

El Camino Hospital has launched a Chinese Health Initiative, designed to address the troubling and unique health disparities in the Silicon Valley's Chinese community and to accommodate their cultural preferences in education, screening and health care delivery.

19 Jan 2011

Transplant surgeons routinely use fewer organs from high-risk donors

As a response to a 2007 episode in which four patients in Chicago were transplanted with organs from a single donor unknowingly infected with HIV — the only such episode in 20 years — one-third of transplant surgeons in the United States "overreacted" and began routinely using fewer organs from high-risk donors, new research from Johns Hopkins finds.

19 Jan 2011

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 2 clinical trial testing the ability of a human monoclonal antibody they developed to prevent hepatitis C virus infection of a donor liver in transplant patients.

19 Jan 2011

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

Two multinational clinical studies indicate that the RDI’s system for predicting how HIV and AIDS patients will respond to different drugs could be a useful tool with potential clinical and economic benefits. The studies, published in the January issue of AIDS Patient Care and STDs, involved highly experienced physicians in the USA, Canada and Italy who used the system to help them select the optimum combination of HIV drugs for patients whose therapy was failing.

18 Jan 2011

Bone marrow stem cell transplantation provides therapeutic benefit to patients with end-stage liver disease

Transplanting their own bone marrow-derived stem cells into 48 patients with end-stage liver disease resulted in therapeutic benefit to a high number of the patients, report researchers publishing in the current issue of Cell Transplantation. Yet, the mechanism by which the infusion of CD34+ stem cells improves liver function remains elusive, they say.

11 Jan 2011

Medical aid workers should take pre-travel precautions to prevent disease transmission

Guidance about pre-travel precautions and preventive measures are highlighted in the December 1, 2010 issue of Clinical Infectious Diseases, written by clinicians and researchers at the Uniformed Services University of the Health Sciences and their partners from the University of Texas Health Sciences Center, Naval Medical Research Center and others.

11 Jan 2011

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

Bristol-Myers Squibb Company and Pharmasset announced today that the companies have entered into a clinical collaboration agreement to evaluate the utility of BMS-790052, Bristol-Myers Squibb's NS5A replication complex inhibitor, in combination with PSI-7977, Pharmasset's nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus.

11 Jan 2011

New lab-on-a-chip technology detects protein in blood less than 30 minutes

While most blood tests require shipping a vial of blood to a laboratory for analysis and waiting several days for the results, a new device invented by a team of engineers and students at the University of Rhode Island uses just a pinprick of blood in a portable device that provides results in less than 30 minutes.

10 Jan 2011

FDA, EMA accept boceprevir for expedited review

Merck, known as MSD outside the United States and Canada, announced today that regulatory applications for boceprevir, Merck's investigational oral hepatitis C virus (HCV) protease inhibitor, were submitted in 2010 and have been accepted for expedited review in both the U.S. and the European Union.

10 Jan 2011

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Inhibitex, today reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus.

10 Jan 2011

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.

7 Jan 2011

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Pharmasset, Inc., announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study.

7 Jan 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Evaluating patients for genetic variations impacts adherence to antiviral therapy

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

CRI, Oncovir sign new investment agreement to produce immunological stimulant

CVAF completes new investment agreement with Oncovir for production of Hiltonol

Pharmasset prices underwritten public offering of 3,300,000 shares of common stock

Opinions: GAVI; Haitian women; Clinton's foreign policy

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

El Camino Hospital introduces CHI program to educate Chinese community on health disparities

Transplant surgeons routinely use fewer organs from high-risk donors

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Clinical studies by expert HIV clinicians suggest that HIV-TRePS may have clinical and economic benefits

Bone marrow stem cell transplantation provides therapeutic benefit to patients with end-stage liver disease

Medical aid workers should take pre-travel precautions to prevent disease transmission

Pharmasset, Bristol-Myers Squibb collaborate for proof of concept study on chronic HCV

New lab-on-a-chip technology detects protein in blood less than 30 minutes

FDA, EMA accept boceprevir for expedited review

Positive results form INX-189 Phase 1b trial against hepatitis C virus

Chimerix initiates enrollment in CMX001 clinical study for life-threatening conditions caused by dsDNA viruses

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in